SCHEMBL14737128

SCHEMBL14737128

COc1ccc(-c2ccc3c(c2)COC3=O)c(OCc2ccc(C(N)=O)cc2)c1OC

nearest known ligand 0.51

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PRF1 P14222 6/20 0.51
PTPN11 Q06124 1/20 0.43
MAOA P21397 4/20 0.43
MAOB P27338 4/20 0.43
ABCG2 Q9UNQ0 3/20 0.42
IMPDH2 P12268 2/20 0.41
SMPD1 P17405 1/20 0.40
PDE4D Q08499 1/20 0.40
ACHE P22303 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7714344 0.96 PRF1 (0.53) PRF1PTPN11MAOAMAOBABCG2
SCHEMBL7713161 0.91 PRF1 (0.46) PRF1PTPN11MAOAMAOBABCG2
SCHEMBL14737349 0.91 PRF1 (0.50) PRF1PTPN11MAOAMAOBABCG2
SCHEMBL14738082 0.89 PRF1 (0.54) PRF1PTPN11MAOAMAOBABCG2
SCHEMBL7711034 0.89 MAOA (0.41) PRF1PTPN11MAOAMAOBABCG2
SCHEMBL14737565 0.85 MAOA (0.45) PRF1MAOAMAOBPDE4D
SCHEMBL2591432 0.85 HSD17B1 (0.42) SMPD1PDE4D
SCHEMBL2590026 0.84 MAOA (0.46) PRF1MAOAMAOBABCG2IMPDH2
SCHEMBL2588546 0.83 PRF1 (0.51) PRF1SMPD1PDE4D
SCHEMBL14737971 0.83 KMT2A (0.40) PRF1MAOBPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP claimed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US claimed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US claimed
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP disclosed
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A PRF1 3550/4885PTPN11 2003/4885MAOA 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.